Age Group – Talk Bio

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

RFK Jr. promotes measles vaccine as Texas outbreak continues

2 weeks ago talkbio0Tagged Case (situation), Disease Outbreaks, Effectiveness, Measles, Measles-Mumps-Rubella Vaccine, RFK gene, Texas, Vaccination, Vaccines

Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas

Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

2 weeks ago talkbio0Tagged Alloimmune thrombocytopenia, Biotech pipeline shift, Fetal and neonatal alloimmune thrombocytopenia, Fetus, immune disorder therapy, Infant, Newborn, Mother (person), Phase 2 clinical trial, Rallybio RLYB212

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift

Entrada given go-ahead to test DMD therapy after two-year hold

2 months ago talkbio0Tagged Adult, DMD, Entrada, Exons, Muscular Dystrophy, Duchenne, United States Food and Drug Administration

Entrada, Muscular Dystrophy, Duchenne, DMD, United States Food and Drug Administration, Adult, Exons

Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up

2 months ago talkbio0Tagged Adolescent (age group), Approved, Bavarian Nordic, chikungunya vaccine, traveler, United States Food and Drug Administration, Vaccines, Virus-Like Particle, Vimkunya

Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers

GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

2 months ago talkbio0Tagged Adolescent (age group), Approved, Invasive meningococcal disease, Meningococcal vaccine, Penmenvy, Pfizer, SmithKline Beecham, United States Food and Drug Administration, Vaccines, Young Adult

Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults